Impact of hepatitis C on HIV progression in adults with alcohol problems

Alcoholism: Clinical and Experimental Research

Volumn 31, Issue 5, 2007, Pages 829-836

  Cheng, Debbie M ^a,b   Nunes, David ^b   Libman, Howard ^c   Vidaver, John ^d   Alperen, Julie K ^b   Saitz, Richard ^a,b   Samet, Jeffrey H ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d DM STAT Inc   (United States)

Author keywords

Alcohol Abuse; Coinfection; Disease Progression; Hepatitis C Virus; HIV

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

ADULT; ALCOHOLISM; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RNA ANALYSIS; SUPERINFECTION;

ADULT; ALCOHOL DRINKING; ALCOHOLISM; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; MODELS, STATISTICAL; PATIENT COMPLIANCE; REGRESSION ANALYSIS; RISK-TAKING; RNA, VIRAL; SAMPLE SIZE; TREATMENT OUTCOME;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 34247101106     PISSN: 01456008     EISSN: 15300277     Source Type: Journal    
DOI: 10.1111/j.1530-0277.2007.00381.x     Document Type: Article

References (59)

1. Alberti A, Clumeck N, Collins S, Gerlich W, Lundgren J, Palu G, Reiss P, Thiebaut R, Weiland O, Yazdanpanah Y, Zeuzem S (2005) Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 42:615-624.
2. Anderson KB, Guest JL, Rimland D (2004) Hepatitis C virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: data from the HIV Atlanta VA Cohort Study. Clin Infect Dis 39:1507-1513.
3. Backus LI, Phillips BR, Boothroyd DB, Mole LA, Burgess J, Rigsby MO, Chang SW (2005) Effects of hepatitis C virus coinfection on survival in veterans with HIV treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 39:613-619.
4. Bare P, Massud I, Belmonte L, Corti M, Villafane M, Perez Bianco R, de Tezanos-pinto M, de Bracco MM, Ruibal-Ares B (2003) HCV recovery from peripheral blood mononuclear cell culture supernatants derived from HCV-HIV co-infected haemophilic patients with undetectable HCV viraemia. Haemophilia 9:598-604.
5. Bare P, Massud I, Parodi C, Belmonte L, Garcia G, Nebel MC, Corti M, Pinto MT, Bianco RP, Bracco MM, Campos R, Ares BR (2005) Continuous release of hepatitis C virus (HCV) by peripheral blood mononuclear cells and B-lymphoblastoid cell-line cultures derived from HCV-infected patients. J Gen Virol 86:1717-1727.
6. Bonacini M, Puoti M (2000) Hepatitis C in patients with human immunodeficiency virus infection: diagnosis, natural history, meta-analysis of sexual and vertical transmission, and therapeutic issues. Arch Intern Med 160:3365-3373.
7. Braitstein P, Yip B, Montessori V, Moore D, Montaner JS, Hogg RS (2005) Effect of serostatus for hepatitis C virus on mortality among antiretrovirally naive HIV-positive patients. Can Med Assoc J 173:160-164.
8. Braitstein P, Zala C, Yip B, Brinkhof MW, Moore D, Hogg RS, Montaner JS (2006) Immunologic response to antiretroviral therapy in hepatitis C Virus-coinfected adults in a population-based HIV/AIDS treatment program. J Infect Dis 193:259-268.
9. Buchsbaum DG, Buchanan RG, Centor RM, Schnoll SH, Lawton MJ (1991) Screening for alcohol abuse using CAGE scores and likelihood ratios. Ann Intern Med 115:774-777.
10. Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, Wu AW (2000) Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 12:255-266.
11. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, Peters MG, Koziel MJ, Bhan AK, Alston B, Colquhoun D, Nevin T, Harb G, van der Horst C (2004) Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 351:451-459.
12. Chung RT, Evans SR, Yang Y, Theodore D, Valdez H, Clark R, Shikuma C, Nevin T, Sherman KE (2002) Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. AIDS 16:1915-1923.
13. Cook RT, Stapleton JT, Ballas ZK, Klinzman D (1997) Effect of a single ethanol exposure on HIV replication in human lymphocytes. J Invest Med 45:265-271.
14. De Luca A, Bugarini R, Lepri AC, Puoti M, Girardi E, Antinori A, Poggio A, Pagano G, Tositti G, Cadeo G, Macor A, Toti M, D'Arminio Monforte A (2002) Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Arch Intern Med 162:2125-2132.
15. Dorrucci M, Pezzotti P, Phillips AN, Lepri AC, Rezza G (1995) Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS. Italian Seroconversion Study. J Infect Dis 172:1503-1508.
16. El-Serag HB, Giordano TP, Kramer J, Richardson P, Souchek J (2005) Survival in hepatitis C and HIV co-infection: a cohort study of hospitalized veterans. Clin Gastroenterol Hepatol 3:175-183.
17. El-Serag HB, Hampel H, Yeh C, Rabeneck L (2002) Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology 36:1439-1445.
18. Fleming CA, Craven DE, Thornton D, Tumilty S, Nunes D (2003) Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis 36:97-100.
19. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state" A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198.
20. Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, Burgisser P, Erb P, Boggian K, Piffaretti JC, Hirschel B, Janin P, Francioli P, Flepp M, Telenti A (2000) Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV cohort study. Lancet 356:1800-1805.
21. Jaggy C, von Overbeck J, Ledergerber B, Schwarz C, Egger M, Rickenbach M, Furrer HJ, Telenti A, Battegay M, Flepp M, Vernazza P, Bernasconi E, Hirschel B (2003) Mortality in the Swiss HIV cohort study (SHCS) and the Swiss general population. Lancet 362:877-878.
22. Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, Hirschel B, Ledergerber B, Vernazza P, Bernasconi E, Rickenbach M, Egger M, Battegay M (2003) CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med 163:2187-2195.
23. Keiser O, Taffe P, Zwahlen M, Battegay M, Bernasconi E, Weber R, Rickenbach M (2004) All cause mortality in the Swiss HIV Cohort Study from 1990 to 2001 in comparison with the Swiss population. AIDS 18:1835-1843.
24. Kertesz SG, Larson MJ, Horton NJ, Winter M, Saitz R, Samet JH (2005) Homeless chronicity and health-related quality of life trajectories among adults with addictions. Med Care 43:574-585.
25. Kessler RC, Andrews G, Mroczek D, Ustun B, Wittchen H (1991) The world health organization composite international diagnostic interview short form (CIDI-SF). Int J Methods Psychiatr Res 7:171-185.
26. Klein MB, Lalonde RG, Suissa S (2003) The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy. J Acquir Immune Defic Syndr 33:365-372.
27. Kresina TF, Flexner CW, Sinclair J, Correia MA, Stapleton JT, Adeniyi-Jones S, Cargill V, Cheever LW (2002) Alcohol use and HIV pharmacotherapy. AIDS Res Hum Retrov 18:757-770.
28. Krupitsky EM, Horton NJ, Williams EC, Lioznov D, Kuznetsova M, Zvartau E, Samet JH (2005) Alcohol use and HIV risk behaviors among HIV-infected hospitalized patients in St. Petersburg, Russia. Drug Alcohol Depend 79:251-256.
29. Laird NM, Ware JH (1982) Random-effects models for longitudinal data. Biometrics 38:963-974.
30. Law WP, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, Lange JM, Phanuphak P, Cooper DA, Dore GJ (2004) Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS 18:1169-1177.
31. Macias J, Pineda JA, Leal M, Abad MA, Garcia-Pesquera F, Delgado J, Gallardo JA, Sanchez-Quijano A, Lissen E (1998) Influence of hepatitis C virus infection on the mortality of antiretroviral-treated patients with HIV disease. Eur J Clin Microbiol Infect Dis 17:167-170.
32. Mayfield D, McLeod G, Hall P (1974) The CAGE questionnaire: validation of a new alcoholism screening instrument. Am J Psychiatry 131:1121-1123.
33. National Institute on Alcohol Abuse and Alcoholism(1995) The Physician's Guide to Helping Patients With Alcohol Problems. National Institute on Alcohol Abuse and Alcoholism, Washington, DC.
34. Nunez M, Soriano V, Lopez M, Ballesteros C, Cascajero A, Gonzalez-Lahoz J, Benito JM (2006) Coinfection with hepatitis C virus increases lymphocyte apoptosis in HIV-infected patients. Clin Infect Dis 43:1209-1212.
35. Pachl C, Todd JA, Kern DG, Sheridan PJ, Fong SJ, Stempien M, Hoo B, Besemer D, Yeghiazarian T, Irvine B, Kolberg J, Kokka R, Neuwald P, Urdea MS (1995) Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay. J Acq Immun Def Synd Hum Retrov 8:446-454.
36. Pawlotsky JM, Bouvier M, Fromont P, Deforges L, Duval J, Dhumeaux D, Bierling P (1995) Hepatitis C virus infection and autoimmune Thrombocytopenic purpura. J Hepatol 23:635-639.
37. Piroth L, Duong M, Quantin C, Abrahamowicz M, Michardiere R, Aho LS, Grappin M, Buisson M, Waldner A, Portier H, Chavanet P (1998) Does hepatitis C virus co-infection accelerate clinical and immunological evolution of HIV-infected patients? AIDS 12:381-388.
38. Quintana M, del Amo J, Barrasa A, Perez-Hoyos S, Ferreros I, Hernandez F, Villar A, Jimenez V, Bolumar F (2003) Progression of HIV infection and mortality by hepatitis C infection in patients with haemophilia over 20 years. Haemophilia 9:605-612.
39. Qurishi N, Kreuzberg C, Luchters G, Effenberger W, Kupfer B, Sauerbruch T, Rockstroh JK, Spengler U (2003) Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 362:1708-1713.
40. Rancinan C, Neau D, Saves M, Lawson-Ayayi S, Bonnet F, Mercie P, Dupon M, Couzigou P, Dabis F, Chene G (2002) Is hepatitis C virus co-infection associated with survival in HIV-infected patients treated by combination antiretroviral therapy? AIDS 16:1357-1362.
41. Robins LN, Wing J, Wittchen HU, Helzer JE, Babor TF, Burke J, Farmer A, Jablenski A, Pickens R, Regier DA, Sartorius N, Towle LH (1988) The Composite International Diagnostic Interview. An epidemiologic Instrument suitable for use in conjunction with different diagnostic systems and in different cultures. Arch Gen Psychiatry 45:1069-1077.
42. Rockstroh JK, Mocroft A, Soriano V, Tural C, Losso MH, Horban A, Kirk O, Phillips A, Ledergerber B, Lundgren J (2005) Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 192:992-1002.
43. Samet JH, Freedberg KA, Savetsky JB, Sullivan LM, Stein MD (2001) Understanding delay to medical care for HIV infection: the long-term non-presenter. AIDS 15:77-85.
44. Samet JH, Horton NJ, Meli S, Freedberg KA, Palepu A (2004a) Alcohol consumption and antiretroviral adherence among HIV-infected persons with alcohol problems. Alcohol Clin Exp Res 28:572-577.
45. Samet JH, Libman H, LaBelle C, Steger K, Lewis R, Craven DE, Freedberg KA (1995) A model clinic for the initial evaluation and establishment of primary care for persons infected with human immunodeficiency virus. Arch Intern Med 155:1629-1633.
46. Samet JH, Phillips SJ, Horton NJ, Traphagen ET, Freedberg KA (2004b) Detecting alcohol problems in HIV-infected patients: use of the CAGE questionnaire. AIDS Res Hum Retroviruses 20:151-155.
47. Schiff ER (1999) The alcoholic patient with hepatitis C virus infection. Am J Med 107:95S-99S.
48. Smith KL, Horton NJ, Saitz R, Samet JH (2006) The use of the mini-mental state examination in recruitment for substance abuse research studies. Drug Alcohol Depend 82:231-237.
49. Sobell LC, Sobell MB (1992) Timeline follow-back: a technique for assessing self-reported alcohol consumption, in Measuring Alcohol Consumption: Psychosocial and Biochemical Methods (Litten RZ, Allen JP eds), pp 41-69. Humana Press, Totowa, NJ.
50. Soriano V, Puoti M, Bonacini M, Brook G, Cargnel A, Rockstroh J, Thio C, Benhamou Y (2005) Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS 19:221-240.
51. Staples CT Jr., Rimland D, Dudas D (1999) Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival. Clin Infect Dis 29:150-154.
52. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL (2002) Hepatitis C and progression of HIV disease. JAMA 288:199-206.
53. Sulkowski MS, Thomas DL (2003) Hepatitis C in the HIV-infected person. Ann Intern Med 138:197-207.
54. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD (2000) Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 283:74-80.
55. Thio CL, Nolt KR, Astemborski J, Vlahov D, Nelson KE, Thomas DL (2000) Screening for hepatitis C virus in human immunodeficiency virus-infected individuals. J Clin Microbiol 38:575-577.
56. Thoren F, Romero A, Lindh M, Dahlgren C, Hellstrand K (2004) A hepatitis C virus-encoded, nonstructural protein (NS3) triggers dysfunction and apoptosis in lymphocytes: role of NADPH oxidase-derived oxygen radicals. J Leukoc Biol 76:1180-1186.
57. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H Jr., Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT (2004) Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl JMed 351:438-450.
58. Weis N, Lindhardt BO, Kronborg G, Hansen AB, Laursen AL, Christensen PB, Nielsen H, Moller A, Sorensen HT, Obel N (2006) Impact of hepatitis C virus coinfection on response to highly active antiretroviral therapy and outcome in HIV-infected individuals: a nationwide cohort study. Clin Infect Dis 42:1481-1487.
59. Zurlo JJ, Wood L, Gaglione MM, Polis MA (1995) Effect of splenectomy on T lymphocyte subsets in patients infected with the human immunodeficiency virus. Clin Infect Dis 20:768-771.